Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.

Article Details

Citation

Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S

Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.

Biochem Biophys Res Commun. 2002 Jan 11;290(1):131-9.

PubMed ID
11779144 [ View in PubMed
]
Abstract

In this study, we used a coactivator-dependent receptor-ligand interaction assay (CARLA), which is a semifunctional in vitro assay, to determine whether hypolipidemic drugs are ligands for the three peroxisome proliferator-activated receptor isotypes (PPARalpha, delta, and gamma). We also evaluated the transcriptional activities of the three PPAR isotypes by transient transfection assays. We found that bezafibrate was a ligand for PPARalpha, delta, and gamma in the CARLA and that bezafibrate induced transcriptional activation of PPARalpha/RXRalpha, PPARdelta/RXRalpha, and PPARgamma/RXRalpha. Although the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors cerivastatin, fluvastatin, and pitavastatin were not ligands for these three nuclear receptors in the CARLA, they induced transcriptional activation of PPARalpha/RXRalpha, PPARdelta/RXRalpha, and PPARgamma2/RXRalpha. Moreover, cerivastatin, fluvastatin, and pitavastatin synergistically and dose-dependently increased the transcriptional activation of PPARalpha/RXRalpha induced by bezafibrate. In addition, the cerivastatin-induced transcriptional activation of PPARalpha/RXRalpha was decreased by addition of mevalonate, farnesol, geranylgeraniol, or cholesterol and by co-transfection with sterol regulatory element-binding protein-1 (SREBP-1). Moreover, concomitant administration of statins and fibrates also decreased the transactivation of nuclear factor kappaB (NFkappaB) and the activation of NFkappaB by mitogen-activated protein kinase kinase kinase (MEKK) also decreased the transactivation of PPARalpha/RXRalpha.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
ClinofibratePeroxisome proliferator-activated receptor alphaProteinHumans
Unknown
Not AvailableDetails
ClinofibratePeroxisome proliferator-activated receptor deltaProteinHumans
Unknown
Not AvailableDetails
ClinofibratePeroxisome proliferator-activated receptor gammaProteinHumans
Unknown
Not AvailableDetails
Fenofibric acidPeroxisome proliferator-activated receptor deltaProteinHumans
Unknown
Unknown
Details
Fenofibric acidPeroxisome proliferator-activated receptor gammaProteinHumans
Unknown
Not AvailableDetails
RosiglitazonePeroxisome proliferator-activated receptor alphaProteinHumans
Unknown
Not AvailableDetails
RosiglitazonePeroxisome proliferator-activated receptor deltaProteinHumans
Unknown
Not AvailableDetails
TroglitazonePeroxisome proliferator-activated receptor alphaProteinHumans
Unknown
Not AvailableDetails
TroglitazonePeroxisome proliferator-activated receptor deltaProteinHumans
Unknown
Not AvailableDetails